OPKO Health Announces Move to NASDAQ Stock Market

MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces
that it will move its stock exchange listing to The NASDAQ Stock Market
from The New York Stock Exchange (the “NYSE”). The Company expects its
common stock will begin trading on the NASDAQ Global Select Market
(“NASDAQ”) on June 24, 2016, and its shares will continue to trade under
the ticker symbol “OPK.”
“NASDAQ is home to many of the world’s best healthcare companies and is
a natural fit for OPKO. This move will enhance our public visibility
while offering our stockholders cost effective access to advanced
trading technologies,” said Phillip Frost, M.D., Chairman and Chief
Executive Officer of OPKO.
Bob Greifeld, CEO of Nasdaq, said, “Under the leadership of Dr. Frost,
OPKO has long been recognized for driving innovation in the
pharmaceutical and diagnostics industries to create products that
improve our lives. We are proud to welcome the company to Nasdaq.”
The Company has notified the NYSE that it will voluntarily delist its
common stock from the NYSE. The last day of trading of the common stock
on the NYSE is expected to be on or about June 23, 2016. Until the
Company’s Common Stock begins trading on NASDAQ, the Company’s Common
Stock will remain trading on NYSE under the ticker symbol “OPK.”
About OPKO Health, Inc.
OPKO Health, Inc. is a diversified healthcare company that seeks to
establish industry-leading positions in large, rapidly growing markets.
Our diagnostics business includes Bio-Reference Laboratories, the
nation’s third-largest clinical laboratory with a core genetic testing
business and a 420-person sales force to drive growth and leverage new
products, including the 4Kscore® prostate cancer test and the Claros®1
in-office immunoassay platform. Our pharmaceutical business features
Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4
chronic kidney disease patients with vitamin D insufficiency and VARUBI™
for chemotherapy-induced nausea and vomiting (oral formulation launched
by partner Tesaro, IV formulation (PDUFA: January 2017)). Our biologics
business includes hGH-CTP, a once-weekly human growth hormone injection
(in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug
for hemophilia (in Phase 2a) and a long acting oxyntomodulin for
diabetes and obesity (in Phase 1). We also have production and
distribution assets worldwide, multiple strategic investments and an
active business development strategy. More information is available at www.opko.com.
This press release contains “forward-looking statements,” as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
“expects,” “plans,” “projects,” “will,” “may,” “anticipates,”
“believes,” “should,” “intends,” “estimates,” and other words of similar
meaning, including statements regarding the transfer of the listing of
the Company’s Common Stock from the NYSE to NASDAQ, the expected start
date of trading on NASDAQ, the enhancement of the Company’s public
visibility, and the cost effective access to our stockholders of
advanced trading technologies. Many factors could cause our actual
activities or results to differ materially from the activities and
results anticipated in forward-looking statements. These factors include
the Company’s ability to continue to comply with the NASDAQ listing
standards and those described in our filings with the Securities and
Exchange Commission. In addition, forward-looking statements may also be
adversely affected by general market factors and federal and state
regulations and legislation, among other factors. The forward-looking
statements contained in this press release speak only as of the date the
statements were made, and we do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.